Drug Trial Radar · NCT03467958
An Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease
Last checked: Nov 20, 2026Latest source record: Sep 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
854
Actual
Start
Aug 24, 2018
Primary completion
Oct 31, 2024
Study completion Oct 31, 2024
Sponsor
- Lead sponsor
- CelgeneBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Mar 16, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an extension study to evaluate safety and efficacy of ozanimod in participants with moderately to severely active Crohn's Disease.
Conditions
- Crohn Disease
Interventions
OzanimodDrug
Specified dose on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Clinical RemissionTime frame: At weeks 48, 96, 144, 192, 240
- Number of Participants With Treatment Emergent Adverse Events (TEAEs)Time frame: From first dose to 90 days post last dose (up to approximately an average of 19 months and a maximum of 65 months)
Locations
766 sites in 49 countries. Site status is shown where the registry gives one.
Holland Center for Family Health
Peoria, Arizona
Local Institution - 202
Scottsdale, Arizona
Local Institution - 026
North Little Rock, Arkansas
Local Institution - 284
Camarillo, California
Sharp Chula Vista Medical Center
Chula Vista, California
Local Institution - 039
Garden Grove, California
Ucsd Medical Center
La Jolla, California
San Diego Clinical Trials
La Mesa, California
Local Institution - 010
Lancaster, California
Local Institution - 061
Los Angeles, California
Southern California Research Institute Medical Group, Inc.
Los Angeles, California
Matrix Clinical Research Inc
Los Angeles, California
Local Institution - 110
Los Angeles, California
Facey Medical Foundation (Parent)
Mission Hills, California
ABS Health, LLC
Mission Viejo, California
Alliance Clinical Research
Oceanside, California
Local Institution - 027
Orange, California
Palo Alto Center-Palo Alto Medical Foundation Research Institute
Palo Alto, California
Havana Research Institute LLC
Pasadena, California
Local Institution - 006
Rialto, California
Sutter Medical Group
Roseville, California
Local Institution - 280
Sacramento, California
Local Institution - 003
San Diego, California
Local Institution - 281
San Francisco, California
New Hope Research Development
West Covina, California
Local Institution - 065
Colorado Springs, Colorado
Local Institution - 297
Lakewood, Colorado
Local Institution - 182
Bristol, Connecticut
Local Institution - 225
Bristol, Connecticut
Local Institution - 091
New Haven, Connecticut
Local Institution - 062
Clearwater, Florida
Clinical Research of West Florida
Clearwater, Florida
South Lake Pain Institute
Clermont, Florida
American Research Institute Inc
Cutler Bay, Florida
Local Institution - 112
Doral, Florida
Riverside Clinical Research
Edgewater, Florida
Local Institution - 218
Gainesville, Florida
Local Institution - 203
Hialeah, Florida
Floridian Clinical Research LLC
Hialeah, Florida
Harmony Medical Research Institute
Hialeah, Florida
Showing 40 of 766 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.